Comparative Pharmacology
Head-to-head clinical analysis: BRIVIACT versus VALRELEASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVIACT versus VALRELEASE.
BRIVIACT vs VALRELEASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
Increases GABAergic transmission by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
500 mg orally twice daily, extended-release formulation. Maximum dose: 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days.
Terminal elimination half-life is 6-16 hours (mean 10.6 h) in adults; shorter at 4-12 h in children due to enhanced clearance; prolonged to 12-18 h in hepatic impairment or elderly. Clinical context: Once-daily dosing requires extended-release formulation (Valrelease) to maintain trough levels.
Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination.
Renal: 70-80% as metabolites (valproic acid glucuronide, 3-oxo-valproate, 2-en-valproate) and <3% unchanged. Hepatic: 15-20% via bile into feces. Other: 1-3% exhaled as CO2.
Category C
Category C
Anticonvulsant
Anticonvulsant